ReviewMolecular therapy : the journal of the American Society of Gene Therapy2026
Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV)-based oncolytic virotherapy has demonstrated promising antitumor effects across various cancer types. However, its application remains limited in scope, and expanding its use to additional cancers poses ongoing challenges. Recently, two other human herpesviruses-varicella-zoster virus (VZV) and cytomegalovirus (CMV)-have emerged as potential platforms for oncolytic virotherapy. In this review, we describe the potential tumor cross-reactivity of the T cell and natural killer (NK) cell responses that are activated and amplified by VZV and CMV, highlighting clinical observations and experimental findings that support the feasibility of redirecting and harnessing these virus-driven immune responses for effective tumor control. We also summarize recent progress in developing oncolytic VZV and CMV vectors, including advances in virus engineering, production, and delivery strategies. This review offers critical insights and highlights key challenges in establishing VZV- and CMV-based cancer viroimmunotherapy platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.